Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects
Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Summary
This study was a randomized, double-blind, single-dose and multi-dose, placebo-controlled phase Ⅰ clinical trial. Six dose groups were planned for the SAD part of the study and four dose groups were planned for the MAD part. A total of 88 healthy subjects were included.
Official title: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Subcutaneous Injections of SHR-6934 in Healthy Subjects: a Randomized, Double-blind, Dose-escalation, Placebo-controlled Phase I Trial
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
88
Start Date
2024-11
Completion Date
2025-08
Last Updated
2024-11-21
Healthy Volunteers
Yes
Conditions
Interventions
SHR-6934 injection
SHR-6934 injection
SHR-6934 placebo
SHR-6934 placebo
Locations (1)
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China